Quarterly report pursuant to Section 13 or 15(d)

Statements of Operations (Unaudited)

v3.23.3
Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development $ 9,477 $ 15,419 $ 34,313 $ 46,872
Research and development - licenses acquired 50 40 50 40
Gain on the sale of property and equipment     0 255
General and administrative 2,131 3,389 7,507 9,815
Total operating expenses 10,307 18,848 40,519 56,727
Loss from operations (10,307) (18,848) (40,519) (56,727)
Other income (expense)        
Other income 138 669 918 669
Interest income 115 216 727 366
Interest expense (4) (1,034) (4,112) (2,199)
Total other income (expense) 249 (149) (2,467) (1,164)
Net Loss $ (10,058) $ (18,997) $ (42,986) $ (57,891)
Net loss per common share outstanding, basic $ (1.23) $ (2.42) $ (5.29) $ (7.61)
Net loss per common share outstanding, diluted $ (1.23) $ (2.42) $ (5.29) $ (7.61)
Weighted average number of common shares outstanding, basic 8,171,582 7,850,208 8,131,191 7,608,309
Weighted average number of common shares outstanding, diluted 8,171,582 7,850,208 8,131,191 7,608,309